Pharma Marketletter

View more issues:

Articles in January, 2004 issue of Pharma Marketletter

• Canada's US envoy slams House Speaker Hastert over drug patent "threat" claims.
• All Bayer's subgroups now separate legal entitites
• Lexapro cleared for new use by FDA
• Euro pharma review built on EMEA's undisputed success, says Liikanen.
• US FDA to halt ephedra dietary supp sales.
• Eisai's pravastatin generic sluggish.
• Axonyx expands phenserine trial to Alzheimer's
• Biomira outlines 2003 milestones.
• UPDATE: AstraZeneca's Exanta gets first approval in France for preventing VTE in surgery.
• Highlights of pharmaceutical mergers and acquisitions during 2003.
• US FTC rules that Schering-Plough, Upsher, AHP illegally delayed generic's entry.
• EU Commission tackles Austria, Belgium and Germany over Rx import curbs.
• Falling FDA approval times due to resource levels, not funding sources, says study.
• Temasek and Newbridge to take stake in Matrix
• Ferring expands infertility portfolio by acquiring Novartis' Norprolac.
• Abbott Labs' Humira marks first successful year.
• Lilly provides 2004 guidance, says acquisitions will weigh on 1st-qtr.
• UK govt seeks L30M for Rx "overcharging".
• WHO/Novartis TB drug deal; other firms urged.
• Spain's Zeltia says EMEA's Yondelis rejection was "close call".
• US NIH director pledges action over staff pharma consulting concerns.
• Fabre takes full control of Dolisos
• Indofarma posts 3rd-qtr 2003 loss
• Bayer defeats EU in parallel imports case.
• EU to probe Turkish pharma trade; local industry fears over data concession.
• Pfizer back on buying spree with $1.3 billion cash bid for Esperion.
• PhRMA views Medicaid Rx coverage high users
• Cell Therapeutics and Novuspharma complete merger
• Appeals court rules for Pfizer
• PI traders tell EC: "fight on" after Bayer ruling.
• Ranbaxy 5th largest generics firm in France.
• Tokyo pharma stocks - week to Jan 5.
• Stock Commentary - New York.
• Aventis files for US approval of Alvesco
• UCB confident on Pharma's future and ups its forecasts for 2003.
• Euro neuropathic pain products market to reach $1.7B by 2012: study.
• Elan sells marketing/ sales ops for $120M
• Study queries COX-2s' cost-effectiveness.
• Stock Commentary - Europe